BR112021019344A8 - Derivados de imidazolina como moduladores de cxcr4 - Google Patents

Derivados de imidazolina como moduladores de cxcr4

Info

Publication number
BR112021019344A8
BR112021019344A8 BR112021019344A BR112021019344A BR112021019344A8 BR 112021019344 A8 BR112021019344 A8 BR 112021019344A8 BR 112021019344 A BR112021019344 A BR 112021019344A BR 112021019344 A BR112021019344 A BR 112021019344A BR 112021019344 A8 BR112021019344 A8 BR 112021019344A8
Authority
BR
Brazil
Prior art keywords
compounds
cxcr4
imidazoline derivatives
modulators
disorder
Prior art date
Application number
BR112021019344A
Other languages
English (en)
Other versions
BR112021019344A2 (pt
Inventor
Bekaddour Benatia Nassima
Rodero Mathieu
Herbeuval Jean-Philippe
Pietrancosta Nicolas
Smith Nikaïa
Barré Anaïs
Cassou Julie
Mayer Stanislas
Original Assignee
Centre Nat Rech Scient
Univ Paris
Univ Paris Cite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Univ Paris, Univ Paris Cite filed Critical Centre Nat Rech Scient
Publication of BR112021019344A2 publication Critical patent/BR112021019344A2/pt
Publication of BR112021019344A8 publication Critical patent/BR112021019344A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

DERIVADOS DE IMIDAZOLINA COMO MODULADORES DE CXCR4. A presente invenção refere-se a compostos de fórmula (I) e composições farmacêuticas contendo esses compostos. Os compostos de fórmula (I) podem atuar como moduladores de CXCR4 que especificamente direcionam a cavidade menor de CXCR4, e eles foram ainda observados de inibir a produção de citocinas inflamatórias em células imunes, o que torna esses compostos altamente vantajosos para uso em terapia, particularmente no tratamento ou prevenção de um distúrbio inflamatório, um distúrbio autoimune, um distúrbio autoinflamatório ou uma interferonopatia, tal como, por exemplo, lúpus eritematoso, dermatomiosite ou artrite reumatoide.
BR112021019344A 2019-03-29 2020-03-27 Derivados de imidazolina como moduladores de cxcr4 BR112021019344A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19305409 2019-03-29
PCT/EP2020/058728 WO2020201096A1 (en) 2019-03-29 2020-03-27 Imidazoline derivatives as cxcr4 modulators

Publications (2)

Publication Number Publication Date
BR112021019344A2 BR112021019344A2 (pt) 2021-12-14
BR112021019344A8 true BR112021019344A8 (pt) 2022-12-06

Family

ID=66102603

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021019344A BR112021019344A8 (pt) 2019-03-29 2020-03-27 Derivados de imidazolina como moduladores de cxcr4

Country Status (12)

Country Link
US (1) US20220144853A1 (pt)
EP (1) EP3947394A1 (pt)
JP (1) JP2022527641A (pt)
KR (1) KR20210146318A (pt)
CN (1) CN113939521A (pt)
AU (1) AU2020255206A1 (pt)
BR (1) BR112021019344A8 (pt)
CA (1) CA3132527A1 (pt)
IL (1) IL286399A (pt)
MX (1) MX2021011599A (pt)
SG (1) SG11202109671WA (pt)
WO (1) WO2020201096A1 (pt)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE565868A (pt) 1957-03-21
DE2348525A1 (de) 1972-09-28 1974-04-11 Searle & Co 2- eckige klammer auf 2-(2-methyl-5nitro-1-imidazolyl)-aethyl eckige klammer zu -2-thio-pseudoharnstoffe
US4205071A (en) 1976-05-14 1980-05-27 Smith Kline & French Laboratories Limited Pharmaceutical compositions having immunosuppressant activity and methods therefor
US4349674A (en) 1978-12-18 1982-09-14 American Home Products Corporation Quinoalinyl esters of carbamimidothioic acids
WO2003029218A1 (fr) 2001-09-28 2003-04-10 Kureha Chemical Industry Company, Limited Compose azote et utilisation correspondante
GB0324498D0 (en) * 2003-07-21 2003-11-26 Aventis Pharma Inc Heterocyclic compounds as P2X7 ion channel blockers
US20190175557A1 (en) 2016-06-16 2019-06-13 Centre National De La Recherche Scientifique Compounds useful for decreasing interferon level

Also Published As

Publication number Publication date
AU2020255206A1 (en) 2021-10-14
JP2022527641A (ja) 2022-06-02
EP3947394A1 (en) 2022-02-09
US20220144853A1 (en) 2022-05-12
WO2020201096A1 (en) 2020-10-08
MX2021011599A (es) 2021-12-10
BR112021019344A2 (pt) 2021-12-14
CA3132527A1 (en) 2020-10-08
CN113939521A (zh) 2022-01-14
KR20210146318A (ko) 2021-12-03
SG11202109671WA (en) 2021-10-28
IL286399A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
MX2020001776A (es) Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
DOP2018000240A (es) Derivados de piridiniltriazol sustituidos con amida y usos de estos
PH12021551065A1 (en) Fused ring compounds
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
TN2018000043A1 (en) Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors
MX2020013853A (es) Compuestos innovadores.
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
EA201890858A1 (ru) 2,4-дигидроксиникотинамиды как агонисты apj
PH12019500731A1 (en) Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
BR112018001469A2 (pt) composto, composição farmacêutica e uso de um composto
BR112018011210A2 (pt) métodos para inibir a conversão de carnitina em trimetilamina (tma)
EA033236B1 (ru) Новые производные пиразола в качестве ингибиторов nik
MX2015013480A (es) Composicion farmaceutica para inhibir la respuesta inmune a traves de la induccion de diferenciacion en celulas t reguladoras y la promocion de proliferacion de celulas t reguladoras.
GEP20217318B (en) Pyrazole magl inhibitors
ZA202001295B (en) Thiazolopyridine derivatives as adenosine receptor antagonists
BR112017004991A2 (pt) compostos antimicrobianos de imidazólio
BR112016006970A2 (pt) enzalutamida em combinação com afuresertib para o tratamento de câncer
BR112015006727A8 (pt) uso de uma composição farmacêutica
NZ756915A (en) Dual magl and faah inhibitors
ZA202001780B (en) Bezimidazole derivatives as adenosine receptor antagonists
MX2021008510A (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina.
SG11201907472QA (en) Composition for inhibiting myofibrosis
BR112021019344A8 (pt) Derivados de imidazolina como moduladores de cxcr4
PH12021550258A1 (en) Cdk8/19 inhibitors
BR112021006424A2 (pt) inibidores de quinase tyk2

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) ; UNIVERSITE PARIS CITE (FR)